Kevin C. Oboyle

Kevin C. Oboyle (board member) discloses dealings in 8 companies, chiefly Wright Medical Group N.V., GenMark Diagnostics, Inc. and Nevro Corp. We count 63 filings; the first trade dates from 26 May 2016 and the latest from 3 June 2026.

In open-market terms, that means 5 purchases worth €335k on one side and 11 sales worth €2.6M on the other. The net balance comes to €2.2M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 35 share grants and 9 option exercises.

The median purchase comes to €74k. On 4 out of 5 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

The record was last updated on 22 June 2026 with a share grant in Carlsmed, Inc. The last purchase on record was published on 16 December 2021, which is 1,770 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.